Timothy Sullivan - Mar 1, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Stock symbol
APLS
Transactions as of
Mar 1, 2024
Transactions value $
-$319,160
Form type
4
Date filed
3/5/2024, 04:04 PM
Previous filing
Feb 13, 2024
Next filing
Apr 2, 2024
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6K -2.24% $0.00 262K Mar 1, 2024 Common Stock 6K $10.03 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F2 This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/1/23.
F3 This option was granted on October 18, 2017 and fully vested.